Sessed the effectiveness of therapy in critically ill escalation Bev Lkerung. The h Higher rates of global success in patients, a step-down therapy in comparison to the reception only anidulafungin expected because NVP-AUY922 the study protocol specified that only patients who have IV therapy addressed erh Hen k nnte Oral azole . Particularly in patients with treatment success at the EOT, the response rates were Similar moments sp Ter independent Ngig of the treatment strategy, suggesting a Similar efficacy of both Ans Tze. Intravascular Has not rkathetervorrichtung distance of 3 days of therapy significantly affected his response to treatment as indwelling catheters were not assessed a potential source of infection, this should especially be treated with caution due. Our study has some RESTRICTIONS Website will.
Due to the design of the study, no direct comparison of anidulafungin with another antifungal therapy is available. Furthermore, certain subgroups of patients only, as they tropicalis of organ transplantation, neutropenia, and C infections. The small sample sizes do not allow meaningful application Ftigen conclusions are drawn on these special populations. In summary, this is the first clinical trial to prospectively evaluate an echinocandin in particular Bev Lkerungsgruppen in intensive care, but with an exploratory approach. The results show that anidulafungin effective treatment and S To R to C / HF in critically ill patients confirm to, with success rates Similar to those obtained with anidulafungin in a general Bev Lkerung.
This efficiency is to be consistent in certain patient groups at high risk, independent Ngig from a variety of clinical factors with the pathogen. Our results support current guidelines recommend echinocandins as first-line therapy for the treatment of C / Cl in m Thirty to critically ill patients. Acknowledgements The first data were presented at the 40th SCCM Critical Care Congress in San Diego, CA, presented as poster # 297th The authors want to m The efforts of all the testing Term doctors of the study and the study team for Pfizer, particularly on Esther ¸ Planc best. Transparency explanation Tion This study was sponsored by Pfizer. Editorial support was provided by Dominik Wolf at PAREXEL available and funded by Pfizer International Operations. Mr.
Ruhnke has once again U is a Forschungsf promotion from Merck, Pfizer and the German Science Stifterverband ¨ fu r, a re U money to speak of Astellas, Essex, Gilead, Merck and Pfizer, and has once again U means the advisory board for Astellas, Essex, Gilead, Merck and Pfizer. A. Paiva re U is a Forschungsf promotion from Merck, Novartis and Pfizer, again U talk about money for MSD, Novartis, and Pfizer, and has once again U of money for the advisory board of Merck, Novartis and Pfizer. W. Meersseman re U is a Forschungsf promotion from Merck and Pfizer, again U talk about money for TMS and re U of money for the advisory board of Pfizer. I. Grigoras has once again U talk about money for Abbott, AstraZeneca, Bayer, Eli Lilly, Fresenius, Merck and Pfizer, and has once again U for money boardfluconazole Advisory, a first-generation triazole, increases hte performance and HRV broader spectrum of activity, but less water- Solubility. HRV is considered as BCS class